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Key message 
Isolated gestational proteinuria (IGP), defined as protein:creatinine ratio > 0.27 mg/mg 
(30 mg/mmol)  in the absence of hypertension, is a prominent risk factor for 
developing preeclampsia (relative risk, 13.1 compared to women without IGP). 
Abstract  
Introduction: Some pregnant women develop significant proteinuria in the absence of 
hypertension. However, clinical significance of isolated gestational proteinuria (IGP) is 
not well understood. This study aimed to determine the prevalence of IGP in singleton 
pregnancies and the proportion of women with IGP who subsequently developed 
preeclampsia (IGP-PE) among all PE cases. 
Material and Methods: This was an observational study of 6819 women with 
singleton pregnancies at 12 centers, including 938 women with at least once 
determination of protein-to-creatinine ratio (P/Cr). Significant proteinuria in pregnancy 
(SPIP) was defined as P/Cr (mg/mg) level > 0.27. IGP was defined as SPIP in the 
absence of hypertension. Gestational hypertension (GH) preceding preeclampsia 
(GH-PE) was defined as preeclampsia (PE) in which GH preceded SPIP. Simultaneous 
PE (S-PE) was defined as PE in which both SPIP and hypertension occurred 
simultaneously. 
Results: IGP and PE were diagnosed in 130 (1.9%) and 158 (2.3%) of 6819 women, 
respectively. Of 130 IGP women, 32 (25%) progressed to PE and accounted for 20% of 
all PE women. Thus, women with IGP had a relative risk of 13.1 (95% CI; 9.2 – 18.5) 
for developing PE compared to those without IGP (25% [32/130] vs. 1.9% [126/6689]). 
At diagnosis of SPIP, P/Cr levels already exceeded 1.0 more often in women with S-PE 
than in those with IGP-PE (67% [33/49] vs. 44% [14/32], respectively, p = 0.031).  
Conclusions: IGP is a risk factor for PE, and IGP-PE accounts for a considerable 
proportion (20%) of all PE. 
Key words: disease pregnancy, pregnancy outcome, proteinuria pregnancy, protein to 
creatinine ratio, preeclampsia 
Abbreviations: GH, gestational hypertension; GH-PE, GH preceding preeclampsia; 
GW, gestational week; IGP, isolated gestational proteinuria; IGP-PE, IGP preceding PE, 
P/Cr, protein-to-creatinine ratio; PE, preeclampsia; S-PE, simultaneous PE; SPIP, 
significant proteinuria in pregnancy 
Introduction 
Preeclampsia (PE) is a life-threatening complication (1) and occurs in approximately 
2.3% of Japanese women (2). Hospitalized care and regular blood tests are currently 
recommended for women diagnosed with PE (3, 4). A diagnosis of PE is made in 
women developing both hypertension and significant proteinuria in pregnancy (SPIP), 
although it has recently been proposed that preeclampsia can be diagnosed in 
hypertensive women with alterations in the liver function, kidney function, and 
hematology in the absence of SPIP (5 – 7). The time between diagnosis of PE and 
delivery is relatively short, within 2 weeks in most cases (8, 9). Early diagnosis of SPIP 
allows early diagnosis of PE and early initiation of intensive monitoring. Hospitalized 
care and regular blood tests would theoretically facilitate early detection of adverse 
conditions associated with PE, such as thrombocytopenia, liver and renal involvement, 
and posterior reversible encephalopathy syndrome, thus leading to earlier delivery with 
improved outcomes, although evidence is lacking.  
Maternal organ systems that are susceptible to excessive inflammation and endothelial 
damage in PE are the central nervous system, lungs, liver, kidneys, systemic vasculature, 
coagulation, and the heart (1). Therefore, clinical manifestations of PE vary between 
individuals; some exhibit SPIP first in the absence of hypertension, so-called “isolated 
gestational proteinuria” (IGP), later developing hypertension and are then diagnosed 
with PE (8, 9). Therefore, IGP is proposed to be an early clinical sign of PE (10). Thus, 
there are three types of PE, i.e., IGP preceding PE in which IGP precedes hypertension, 
gestational hypertension (GH) preceding PE in which GH precedes SPIP, and PE in 
which hypertension and SPIP occur simultaneously (8,9,11). In a previous small 
single-center study (8), PE occurred in 19 of 37 IGP women (51%) approximately two 
weeks after the confirmation of IGP (8), thus suggesting that IGP was a prominent risk 
factor for PE. However, there have been no studies assessing how many women develop 
IGP, how many IGP women later develop hypertension, and what percentage of all PE 
cases are preceded by IGP. Addressing these issues may help to gain a better 
understanding of the nature of PE.  
This multicenter retrospective observational study was conducted to determine the 
prevalence of IGP in singleton pregnancies and the proportion of women with IGP who 
subsequently developed preeclampsia (IGP-PE) among all PE cases. 
Material and methods 
This retrospective observational study was conducted after receiving approval from the 
Institutional Review Board of Hokkaido University Hospital (013-3999, April 30, 2014). 
The Japan Society of Obstetrics and Gynecology recommends 14 – 15 antenatal care 
visits before delivery and that pregnant women should undergo determination of blood 
pressure, proteinuria by dipstick test, and body weight at each visit (4). In this study, no 
definite protocols were predefined regarding the use of spot urine protein-to-creatinine 
ratio (P/Cr) test for confirmation of SPIP after obtaining dipstick test results. Therefore, 
the performance of the P/Cr test was at the attending physician’s discretion. However, in 
2014, the Japan Society of Obstetrics and Gynecology recommended use of the P/Cr 
test with a threshold of 0.27 (mg/mg, corresponding to 30 mg/mmol) in women with the 
following dipstick test results: ≥ 1+ in the presence of hypertension, and ≥ 1+ on two 
successive antenatal care visits, and ≥ 2+ even in the absence of hypertension (4).  
In this study, we abstracted the medical records of all 938 women with singleton 
pregnancies that underwent a P/Cr test at least once from a total of 6984 women (Fig. 1). 
The database provided by the institutional central laboratory of participating facilities 
helped to identify women who had a P/Cr test at least once. SPIP was defined as P/Cr > 
0.27 (mg/mg, corresponding to 30 mg/mmol) in spot urine specimen (3,4,6,7,12 – 14), 
and IGP was defined as SPIP in the absence of hypertension. Hypertension was defined 
as the occurrence of systolic blood pressure ≥ 140 mmHg and/or diastolic blood 
pressure ≥ 90 mmHg and GH was defined as hypertension occurring on and after 
gestational week (GW) 20 in the absence of SPIP. PE was diagnosed in women who 
developed both hypertension and SPIP. Women with IGP or GH were followed-up once 
or more per week on an outpatient basis, and were admitted to one of the 12 
participating hospitals when they were diagnosed as having PE. The GW at new onset 
of hypertension and SPIP was specified in each subject, and PE was classified into one 
of three types according to the timing of the onsets of hypertension and SPIP: 
simultaneous PE (S-PE) in which both hypertension and SPIP were confirmed on the 
same day, IGP preceding PE (IGP-PE) in which IGP occurred earlier than hypertension, 
and GH preceding PE (GH-PE) in which hypertension occurred earlier than SPIP.  
In this study, no definite protocols were predefined regarding the use of induction of 
labor in PE patients. Therefore, PE patients were managed according to the policies at 
each institution. The Japan Society of Obstetrics and Gynecology recommends early 
delivery in PE women with one or more of the following conditions (4): uncontrollable 
hypertension exceeding systolic blood pressure ≥ 180 mmHg and/or diastolic blood 
pressure ≥ 110 mmHg even with antihypertensive agents; net weight gain ≥ 3.0 kg per 
week; liver dysfunction as evidenced by elevated aspartate aminotransferase (> 45 
IU/L) level and/or elevated level of lactate dehydrogenase (> 400 IU/L) concomitant 
with reduced platelet count (< 100×109/L) and/or reduced antithrombin activity level (< 
60% of normal activity level); and an increase in proteinuria with P/Cr test result 
exceeding 5.0. 
The following 12 facilities located throughout Japan participated in this study: 
Hiroshima University Hospital, Rakuwakai Otowa Hospital, Ohno Ladies Clinic, Mie 
Chuo Medical Center, Mie University Hospital, Nippon Medical School Tama 
Nagayama Hospital, Juntendo University Hospital, University of Tsukuba Hospital, 
Jichi Medical University Hospital, Fukushima Medical University Hospital, Hakodate 
Central General Hospital, and Hokkaido University Hospital. The clinical data, 
including patient age, parity, and clinical outcomes were obtained from medical charts 
of women with IGP, GH and PE.  
Statistical analyses 
Data are presented as median (range). Statistical analyses were performed using the 
JMP Pro11© statistical software package (SAS, Cary, NC). The Tukey–Kramer method 
was used for comparison of medians. Pearson’s chi-square test was used for comparison 
of categorical variables. In all analyses, p < 0.05 was taken to indicate statistical 
significance. 
Results 
The flow of study participant is shown in figure 1. A total of 130 women were 
identified as having IGP, corresponding to 1.9% (130/6819) of the background pregnant 
population (n = 6819) (Fig. 1). Thirty-two (25%) of the 130 women with IGP later 
developed hypertension and were diagnosed with IGP-PE. GH-PE and S-PE were 
diagnosed in 77 and 49 of the 327 women included in the study population, respectively. 
Thus, IGP-PE women accounted for 20% (32/158) of all PE women. The total number 
of PE cases, i.e., 158, corresponded to 2.3% (158/6819) of the background population. 
Compared to 6689 women that were not diagnosed as having IGP, the risk of 
developing PE was significantly greater in the 130 women with IGP (25% [32/130] vs. 
1.9% [126/6689], respectively, p < 0.0001) and the relative risk (95% confidence 
interval [CI]) of developing PE was 13.1 (95% CI; 9.2 – 18.5) for women with IGP. 
The clinical characteristics were compared between groups (Table 1). Hypertension was 
diagnosed significantly earlier in the GH-PE group than the S-PE group. GW at the 
diagnosis of SPIP did not differ significantly between groups. The time interval 
between confirmation of SPIP and delivery was significantly longer in the IGP-PE 
group than in the other two PE groups. SPIP was confirmed postpartum for the first 
time in 15 of the 77 women (19%) with GH-PE. There were no significant differences 
in variables shown in Table 1 between 62 and 15 GH-PE women with SPIP confirmed 
ante- and postpartum, respectively, except for the GW at onset of hypertension (32.7 ± 
4.0 vs. 35.1 ± 3.4, respectively, p = 0.03). Thus, GH-PE women with antepartum SPIP 
developed hypertension earlier compared to those with postpartum SPIP.  
In this study, SPIP was diagnosed in women with P/Cr > 0.27. The P/Cr test was 
performed 96, 188, and 125 times for 32, 77, and 49 women diagnosed with IGP-PE, 
GH-PE, and S-PE, respectively (Table 2). The number of women with ≥ 3 P/Cr tests 
was significantly greater in the IGP-PE group than in the other two PE groups. There 
were no significant differences in protein concentration, creatinine concentration, or 
P/Cr level at diagnosis of SPIP between the three PE groups. However, the number of 
women with a P/Cr level > 1.0 at diagnosis of SPIP was significantly greater in the 
S-PE group than in the other two PE groups although GW at the diagnosis of SPIP did 
not differ significantly between groups; 67% (33/49) vs. 44% (14/32) with p =0.03 for 
S-PE vs. IGP-PE, respectively and 67% [33/49] vs. 44% [34/77] with p =0.009 for S-PE 
vs. GH-PE, respectively (Table 2, Fig. 2B). 
The P/Cr level appeared to increase with advancing gestational age in most patients 
with PE, although the rate of increase in P/Cr level (per unit time) varied greatly 
between individuals (Fig. 2A). Distribution of P/Cr level at the diagnosis of SPIP is 
shown in Fig. 2B.  
Discussion 
In this study, 1.9% (130/6819) of women with singleton pregnancies exhibited IGP 
defined as P/Cr level > 0.27 in the spot urine sample in the absence of hypertension, 
25% (32/130) of IGP women later progressed to PE, and IGP-PE accounted for 20% 
(32/158) of all PE women. In a recent study by Samo et al. (15), IGP-PE accounted for 
25% of all 195 PE women. 
The gold standard for diagnosis of SPIP is proteinuria ≥300 mg in 24-hour urine (5 – 7), 
although PE can be diagnosed without confirmation of SPIP in hypertensive women 
with certain clinical conditions according to recent guidelines (5 – 7). We speculated 
that problems inherent in 24-hour urine collection may have prevented determination of 
the numbers of women exhibiting IGP, the numbers of women with IGP progressing to 
PE, and the percentage of IGP preceding PE in all cases of PE. To our knowledge, most 
guidelines (3, 5 – 7) for the diagnosis and treatment of hypertensive disorders in 
pregnancy do not mention the prevalence of IGP due to a lack of reports in the literature. 
This lack of reports may be due to difficulty in performing studies addressing these 
issues for several reasons. Convenient P/Cr testing using random urine samples has only 
recently been introduced in obstetric practice as an alternative to 24-hour urine 
collection (3 – 7). The rate of false positive test results on dipstick test is high due to the 
inherent nature of this primary screening tool for SPIP, especially in concentrated urine 
samples (16 - 19). Although 24-hour urine collection has been mandatory for diagnosis 
of SPIP, it is frequently incomplete and inconvenient for pregnant women (18 – 20); 
therefore, physicians may be reluctant to ask women for repeated 24-hour urine 
collection.  
Our study design did not preclude the possibility that there may have been some women 
with IGP among the 5881 women that did not undergo P/Cr test at all during pregnancy 
(Fig. 1). However, it was notable that there were at least 130 IGP women, 
corresponding to 1.9% of the whole background population. In a recent study by Ekiz et 
al. defining SPIP as protein loss ≥ 300 mg in 24-hour urine samples (21), a much lower 
IGP prevalence rate of 0.5% (157/31 472) was reported. We speculate that this 
difference in IGP prevalence rate may have been due to difficulty in performing the 
24-hour urine collection test. The P/Cr test was performed in 938 of all 6819 women 
(14%) (Fig. 1) and 409 times in the 158 PE women before and/or after the diagnosis of 
PE (Table 2) in this study.  
The risk of PE among IGP women was 25% (32/130) in this study, which was relatively 
consistent with that of 34% (53/157) in the study by Ekiz et al. (21). This clearly 
indicated that IGP is a risk factor for PE. The number of women diagnosed with PE in 
our setting corresponded to 2.3% of the whole background population of 6819 women, 
which was consistent with the results of a previous study in which the prevalence rate of 
PE based on traditional criteria for diagnosis was 2.3% among 301 735 pregnant 
Japanese women with singleton pregnancies (2). The risk of PE was estimated as 1.9% 
(128/6689) among women not diagnosed with IGP in this study, which was much lower 
than the rate of 25% among women with IGP, indicating a relative risk of 13.1 for 
developing PE in IGP women. Thus, IGP was an apparent prominent risk factor for PE 
in this study.  
In this study, the number of women with a P/Cr level > 1.0 at diagnosis of SPIP was 
significantly greater in the S-PE group than in the other two PE groups (Table 2, Fig. 
2B). Three previous studies (8, 9, 22) suggested that proteinuria increased with 
advancing gestational age. However, it was suggested that the rate of increase in 
proteinuria varied greatly between individuals in this study (Fig. 2A).  
In conclusion, the present study demonstrated that IGP, defined as P/Cr > 0.27 (30 
mg/mmol) in the absence of hypertension, is a risk factor for developing PE. IGP-PE 
accounts for a considerable proportion (20%) of all cases of PE. This knowledge may 
contribute to earlier diagnosis of PE and earlier delivery when indicated to improve 
outcomes in such women with IGP-PE.   
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Figure Legends 
Figure 1 Flow diagram of the study participants 
GH, gestational hypertension; GH-PE, GH preceding preeclampsia (PE); GW, 
gestational week; IGP, isolated gestational proteinuria; IGP-PE, IGP preceding PE; SPIP, 
significant proteinuria in pregnancy (defined as P/Cr > 0.27); S-PE, simultaneous PE.  
Shaded columns indicate 327 women who were abstracted from 6984 women after 
meeting all of the following four conditions: (1) singleton pregnancy, (2) new onset of 
SPIP or hypertension on and after GW 20, (3) no known renal diseases, and (4) no 
known hypertension. There were 6819 maternities carrying singletons at 12 centers 
during the 1-year study period between April 2014 and March 2015. The institutional 
central laboratory database identified 938 women with at least one P/Cr test, including 
294 women with SPIP and 644 women without SPIP. The hospital discharge record 
database for the 644 women without SPIP identified 89 women with hypertensive 
disorders in pregnancy including chronic hypertension defined as hypertension 
confirmed before GW 20. The medical charts for each of the 294 women with SPIP and 
the 89 women with hypertension but without SPIP were reviewed. Gestational week at 
the new onset of SPIP and or hypertension was specified in the medical charts for each 
woman. Then, 56 women with known renal diseases, chronic hypertension, and or P/Cr 
> 0.27 before GW 20 were excluded.  
Figure 2 Antenatal changes in P/Cr ratio (A) and P/Cr ratio at the diagnosis of 
SPIP (B) 
A: The shaded area indicates P/Cr ratio < 0.27. Twenty-three of 32 women with IGP-PE, 
28 of 77 women with GH-PE, and 21 of 49 women with S-PE underwent P/Cr test at 
least twice antepartum, and were shown to have SPIP antepartum (15 of the 77 women 
with GH-PE exhibited SPIP postpartum for the first time). The P/Cr ratio increased with 
advancing gestation in most PE patients, although the rate of increase of proteinuria 
varied greatly between individuals.  
B: Distribution of P/Cr ratio at the diagnosis of SPIP is shown. Number of women with 
P/Cr > 1.0 is indicated in rectangles. A significantly greater number of women exhibited 
P/Cr > 1.0 at the diagnosis of SPIP in women with S-PE (67% [33/49]) than in those 
with IGP-PE (44% [14/32]) and GH-PE (44% [34/77]).  
Figure 1
F i g u r e  2
Table 1 Demographic characteristics of 327 women      
  IGP (n=130)   GH (n=148)   S-PE (n=49)  
Final diagnosis IGP (n=98) IGP-PE (n=32) GH (n=71) GH-PE (n=77)   
Maternal age (yr) 31 (18-44) 33 (19-42) 34 (17-45) 35 (19-45) 34 (16- 41) 
Nulliparous women 61 (62.2%) 23 (71.9%) 40 (56.3%) 46 (59.7%)a 37 (75.5%)a
GW at onset 
  SPIP 35.0 (21.6–40.9) 33.3 (24.7-39.6) NA 35.0 (23.9-PPW 0.9) 36.7 (23.6-41.1) 
  Hypertension NA 36.0 (24.9-40.4) 35.9 (20.0-40.3) 33.7 (23.4-40.4)a   36.7 (23.6-41.1)a
Interval (weeks)‡   2.2 (-1.0 – 17.4)a, b 1.3 (0.2 – 11.7)c, d NA 0.5 (0.0 – 7.0)a, c 0.3 (0.0 – 6.9)b, d 
GW at delivery 38.8 (23.9-41.6)a, b 37.0 (25.3-40.7) 37.9 (27.0-41.6)c 36.4 (24.1-41.3) a, c 37.1 (23.7-41.3)b
    < 37 20 (20.4%)a, b 16 (50.0%)c 19 (26.8%)c, d, e 44 (57.1%)a, d 22 (44.9%)b, e 
Birth-weight (kg) 2.91 (0.62-3.98)a, b, c 2.20 (0.37-3.44)a, d 2.80 (0.67-4.01)d, e 2.15 (0.38-3.79)b, e 2.56 (0.44-4.06)c    
Data are presented as the median (range) or number (percentage). ‡, Time interval until delivery after SPIP confirmation. Significant 
difference was compared between three groups including IGP-PE, GH-PE, and S-PE; P < 0.05 between two figures with superscript. 
GH, gestational hypertension; IGP, isolated gestational proteinuria; GW, gestational week; GH-PE, hypertension-preceding 
preeclampsia; IGP-PE, proteinuria-preceding preeclampsia; PPW, postpartum week; S-PE, simultaneous preeclampsia; SPIP, 
significant proteinuria in pregnancy. The 130 women with IGP developed SPIP at GW 34.9 (21.6–40.9) and 148 women with GH 
developed hypertension at GW 34.4 (20.0-40.4). SPIP was confirmed postpartum for the first time in 15 of the 77 women with 
GH-PE. 
Table 2  P/Cr tests performed in three groups                                    
              Final diagnosis                            
   IGP-PE  GH-PE  S-PE             
No. of women  32  77  49 
Total no. of P/Cr tests 96  188  125 
No. of P/Cr tests/person 3 (1 – 5) 2 (1 – 5) 2 (1 – 5) 
  Once   6 (18.8%)  18 (23.4%) 14 (28.6%) 
  Twice   4 (12.5%)  23 (29.9%) 12 (24.5%) 
  Three times or more 22 (68.8%)a 36 (46.8%)a 23 (46.9%) 
When SPIP was diagnosed  
  [P] (mg/dL)  98 (10 – 683) 74 (9.1 – 3890) 158 (9.0 – 2396) 
  [Cr] (mg/dL)  122 (26 – 335) 91 (18 – 401) 119 (20 – 374) 
  P/Cr (mg/mg)  0.81 (0.32 – 5.6) 0.92 (0.27 – 21.7) 1.48(0.27 – 13.8) 
 < 0.5     9 (28.1%)  24 (31.2%)a 7 (14.3%)a  
  > 1.0       14 (43.8%)a 34 (44.2%)b 33 (67.4%)a,b 
  > 1.5                  10 (31.3%) 27 (35.1%) 24 (49.0%) 
  > 2.0   6 (18.8%)  24 (31.2%) 19 (38.8%) 
  Dipstick test result 
   Negative/equivocal   1 (3.1%)  13 (16.9%) 3 (6.1%) 
   1+   10 (31.3%) 20 (26.0%) 9 (18.4%) 
   ≥ 2+   21 (65.6%) 44 (57.1%)a 37 (75.5%)a     
Data are presented as the median (range) or number (percentage). [P], protein concentration; [Cr], 
creatinine concentration. P < 0.05 between two figures with superscript. 
 
 
